Homburger advises VectivBio on its acquisition of Comet Therapeutics

On August 31, 2021, VectivBio Holding AG announced the acquisition of Comet Therapeutics, Inc., a biotechnology company that has been developing drugs to address previously untreatable inherited metabolic diseases. This acquisition significantly expands VectivBio’s rare disease pipeline.

VectivBio will acquire Comet Therapeutics in exchange for equity and cash payable at closing, as well as additional equity or cash payments upon the achievement of future development milestones. The transaction is expected to close by the end of September 2021, subject to customary closing conditions.

Homburger advises VectivBio Holding AG in this matter. The Homburger team includes partner Andreas Müller, associates Margrit Marti, Angela Oppliger and Kevin Hubacher (all Corporate / M&A), partner Stefan Oesterhelt and associate Joël Gyger (both Tax).